抄録
Aim: Hypoxia-inducible factor (HIF) contributes to the adaptation of tumor cells to hypoxic conditions, so genetic polymorphisms involved in this pathway may affect cellular response to hypoxia and be associated with cancer risk. Thus, we examined the association between the lung cancer risk and genetic polymorphisms involved in the HIF pathway. Methods: This case–control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of HIF1A rs11549467, HIF1A rs11549465, HIF1A rs2057482, HIF2A rs13419896 and vascular endothelial growth factor A (VEGFA) rs833061 on the risk of lung cancer using TaqMan real-time PCR assay. Logistic regression was used to estimate the odds ratio (OR) and its 95% confidence interval (CI) of lung cancer risk. The multiplicative and additive interactions with cigarette smoking were also examined. Results: The AA genotype of HIF2A rs13419896 (OR = 0.54, 95% CI = 0.30–0.99) and the CC genotype of VEGFA rs833061 (OR = 0.42, 95% CI = 0.24–0.75) were significantly associated with a decreased risk of lung cancer after adjustment of potential covariates. Additive interactions between these two polymorphisms and cigarette smoking were also significant. Conclusion: HIF2A rs13419896 and VEGFA rs833061 were significantly related to lung cancer risk, with possible interaction between polymorphisms and cigarette smoking. Further studies are needed to confirm these results.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 234-242 |
| ページ数 | 9 |
| ジャーナル | Asia-Pacific Journal of Clinical Oncology |
| 巻 | 13 |
| 発行部数 | 3 |
| DOI | |
| 出版物ステータス | 出版済み - 6 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
これを引用
Association between genetic polymorphisms involved in the hypoxia-inducible factor pathway and lung cancer risk : a case–control study in Japan. / Yamamoto, Yuzo; Kiyohara, Chikako; Ogata-Suetsugu, Saiko; Hamada, Naoki; Nakanishi, Yoichi.
：: Asia-Pacific Journal of Clinical Oncology, 巻 13, 番号 3, 01.06.2017, p. 234-242.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Association between genetic polymorphisms involved in the hypoxia-inducible factor pathway and lung cancer risk
T2 - a case–control study in Japan
AU - Yamamoto, Yuzo
AU - Kiyohara, Chikako
AU - Ogata-Suetsugu, Saiko
AU - Hamada, Naoki
AU - Nakanishi, Yoichi
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Aim: Hypoxia-inducible factor (HIF) contributes to the adaptation of tumor cells to hypoxic conditions, so genetic polymorphisms involved in this pathway may affect cellular response to hypoxia and be associated with cancer risk. Thus, we examined the association between the lung cancer risk and genetic polymorphisms involved in the HIF pathway. Methods: This case–control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of HIF1A rs11549467, HIF1A rs11549465, HIF1A rs2057482, HIF2A rs13419896 and vascular endothelial growth factor A (VEGFA) rs833061 on the risk of lung cancer using TaqMan real-time PCR assay. Logistic regression was used to estimate the odds ratio (OR) and its 95% confidence interval (CI) of lung cancer risk. The multiplicative and additive interactions with cigarette smoking were also examined. Results: The AA genotype of HIF2A rs13419896 (OR = 0.54, 95% CI = 0.30–0.99) and the CC genotype of VEGFA rs833061 (OR = 0.42, 95% CI = 0.24–0.75) were significantly associated with a decreased risk of lung cancer after adjustment of potential covariates. Additive interactions between these two polymorphisms and cigarette smoking were also significant. Conclusion: HIF2A rs13419896 and VEGFA rs833061 were significantly related to lung cancer risk, with possible interaction between polymorphisms and cigarette smoking. Further studies are needed to confirm these results.
AB - Aim: Hypoxia-inducible factor (HIF) contributes to the adaptation of tumor cells to hypoxic conditions, so genetic polymorphisms involved in this pathway may affect cellular response to hypoxia and be associated with cancer risk. Thus, we examined the association between the lung cancer risk and genetic polymorphisms involved in the HIF pathway. Methods: This case–control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of HIF1A rs11549467, HIF1A rs11549465, HIF1A rs2057482, HIF2A rs13419896 and vascular endothelial growth factor A (VEGFA) rs833061 on the risk of lung cancer using TaqMan real-time PCR assay. Logistic regression was used to estimate the odds ratio (OR) and its 95% confidence interval (CI) of lung cancer risk. The multiplicative and additive interactions with cigarette smoking were also examined. Results: The AA genotype of HIF2A rs13419896 (OR = 0.54, 95% CI = 0.30–0.99) and the CC genotype of VEGFA rs833061 (OR = 0.42, 95% CI = 0.24–0.75) were significantly associated with a decreased risk of lung cancer after adjustment of potential covariates. Additive interactions between these two polymorphisms and cigarette smoking were also significant. Conclusion: HIF2A rs13419896 and VEGFA rs833061 were significantly related to lung cancer risk, with possible interaction between polymorphisms and cigarette smoking. Further studies are needed to confirm these results.
UR - http://www.scopus.com/inward/record.url?scp=85006922888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006922888&partnerID=8YFLogxK
U2 - 10.1111/ajco.12640
DO - 10.1111/ajco.12640
M3 - Article
C2 - 27981753
AN - SCOPUS:85006922888
VL - 13
SP - 234
EP - 242
JO - Asia-Pacific Journal of Clinical Oncology
JF - Asia-Pacific Journal of Clinical Oncology
SN - 1743-7555
IS - 3
ER -